leuprolide acetate for depot suspension / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 138 Diseases   93 Trials   93 Trials   2194 News 


«12345678910111213...3334»
  • ||||||||||  enzalutamide capsule / Generic mfg., leuprolide acetate for depot suspension / Generic mfg.
    PSMA PET findings in an  (On Demand | Hall A; Poster Bd # 185) -  Apr 26, 2023 - Abstract #ASCO2023ASCO_1659;    
    P3
    Background: The EMBARK trial is a phase 3, randomized, study evaluating use of enzalutamide with or without concomitant leuprolide in non-metastatic castrate sensitive prostate cancer patients. In this
  • ||||||||||  Xtandi (enzalutamide) / Pfizer, Astellas
    Trial initiation date:  ARCH: Contributions to Hypertension With Androgen Deprivation Therapy (clinicaltrials.gov) -  Apr 25, 2023   
    P4,  N=228, Not yet recruiting, 
    Addressing this is important, because the acknowledgement of adverse effects is central to regulatory decisions and the protection of public health. Initiation date: Apr 2023 --> Jul 2023
  • ||||||||||  sunitinib / Generic mfg.
    Trial completion date, Trial primary completion date:  Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy (clinicaltrials.gov) -  Apr 25, 2023   
    P2,  N=64, Active, not recruiting, 
    Initiation date: Apr 2023 --> Jul 2023 Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
  • ||||||||||  Opdivo (nivolumab) / BMS
    Trial suspension:  Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors (clinicaltrials.gov) -  Apr 13, 2023   
    P2,  N=60, Suspended, 
    N=200 --> 94 | Trial completion date: Feb 2025 --> Apr 2026 | Trial primary completion date: Feb 2024 --> Apr 2025 Recruiting --> Suspended
  • ||||||||||  Suprefact (buserelin acetate) / Sanofi
    Trial primary completion date:  Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer (clinicaltrials.gov) -  Apr 4, 2023   
    P3,  N=192, Recruiting, 
    Consuming less resources without negatively impacting on health outcomes carries ethical and practical implications for individuals and the community, as this approach may result in overall increased healthcare access. Trial primary completion date: Dec 2021 --> Dec 2025
  • ||||||||||  Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
    Review, Journal, Metastases:  Relugolix: A Review in Advanced Prostate Cancer. (Pubmed Central) -  Mar 29, 2023   
    Furthermore, there is evidence that relugolix may be associated with a lower risk of major adverse cardiac events compared with leuprolide. With the ability to provide the rapid testosterone suppression (with no initial surge in testosterone upon treatment initiation) combined with the benefits of oral administration and potentially improved cardiac safety, relugolix presents a valuable treatment option for men with advanced prostate cancer where androgen deprivation therapy is indicated.
  • ||||||||||  Firmagon (degarelix) / Astellas, Ferring
    A Curious Case of Isolated Mediastinal Prostate Cancer Recurrence (Walter E. Washington Convention Center, Area J, Hall C (Lower Level)) -  Mar 25, 2023 - Abstract #ATS2023ATS_8754;    
    It also highlights the importance of considering the prostate as a possible source of origin in metastatic adenocarcinoma. It is reasonable to recommend immuno-cytochemical stains for PSA to all mediastinal biopsy specimens showing adenocarcinoma in male patients and following up with prostatic aspiration cytology/biopsy in case of elevated PSA.
  • ||||||||||  De Novo Prostate Adenocarcinoma in a Lung Transplant Recipient: Immune-surveillance or Immune-suppression? (Walter E. Washington Convention Center, Area A, Hall C (Lower Level)) -  Mar 25, 2023 - Abstract #ATS2023ATS_7967;    
    Posttransplant immunosuppression included tacrolimus, mycophenolate mofetil, and prednisone...Androgen deprivation therapy (ADT) with bicalutamide for 7-14 days and 3 monthly leuprolide treatments were started in August 2022...Due to the increased risk of toxicities, comorbidities, and physical deconditioning, our patient was not a candidate for abiraterone, docetaxel, NRG-GU007 (PARP inhibitor), or NRG-GU009 (genomic assay for risk assessment)...Active surveillance should be maintained. A delicate balance between immune surveillance to contain malignancy and immunosuppression to prevent allograft rejection is warranted.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    A Man With Palbociclib-Induced Pneumonitis: A Very Rare Entity (Walter E. Washington Convention Center, Room 103 A-B (Street Level)) -  Mar 25, 2023 - Abstract #ATS2023ATS_3515;    
    He was receiving his second cycle of palbociclib along with letrozole, leuprolide and denosumab...He was initially treated for community acquired pneumonia with ceftriaxone and azithromycin...Palbociclib was also discontinued. Bronchoscopy may not always be needed to confirm or excluded other pathology in the appropriate clinical context especially in severe cases.
  • ||||||||||  letrozole / Generic mfg., leuprolide acetate for depot suspension / Generic mfg.
    Impact of Ovulation Induction in a Patient With Lymphangioleiomyomatosis (Walter E. Washington Convention Center, Room 209 A-C (Level 2)) -  Mar 25, 2023 - Abstract #ATS2023ATS_3216;    
    A lower rise in estrogen may explain the lack of lung function decline in our case. With the increasing use of assisted reproductive techniques, research regarding its impact on patients with hormone-sensitive conditions like LAM is needed.
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg.
    Enrollment open:  Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy (clinicaltrials.gov) -  Mar 23, 2023   
    P3,  N=40, Recruiting, 
    Goserelin and leuprorelin were comparable in terms of ovarian protection during doxorubicin/cyclophosphamide-based chemotherapy in young patients with breast cancer. Not yet recruiting --> Recruiting
  • ||||||||||  enzalutamide capsule / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., abiraterone acetate / Generic mfg.
    Role of AKR1C3 in converting reservoirs of DHEA-S into potent androgens that drive prostate cancer cell growth (Room W311 E-H - Convention Center) -  Mar 14, 2023 - Abstract #AACR2023AACR_5552;    
    Through inhibition of CYP17A1, Abiraterone (Abi) prevents an upstream step in androgen biosynthesis, while Enzalutamide (ENZ) acts as an AR antagonist...we observed in patients on Leuprolide that T was reduced to 5 ng/dL, and the addition of Abi lowered DHEA-S by 90% (from 230,000 ng/dL to 22,000 ng/dL)...Additionally, we demonstrate AKR1C3-dependence using genetic and pharmacological approaches with an AKR1C3 stable knockdown for each cell line and two AKR1C3 competitive inhibitors. Taken together, we have identified a mechanism of resistance to ARSIs common to both primary and metastatic cell lines that operates through AKR1C3
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg.
    Investigating cholesterol transfer between macrophages and prostate cancer cells (Section 21; Poster Board #19) -  Mar 14, 2023 - Abstract #AACR2023AACR_5161;    
    We have previously shown in a murine model of CRPC that macrophages promote AR signaling in CRPC and that depleting tumor macrophages extends survival in response to ADT with Lupron... Cholesterol transfer between macrophages and prostate cancer cells occurs in a contact-dependent manner, independently of the scavenger receptors most commonly associated with cholesterol accumulation.
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg., bicalutamide / Generic mfg.
    Opposing roles of SPOP mutations in human prostate and endometrial cancers (Section 38; Poster Board #20) -  Mar 14, 2023 - Abstract #AACR2023AACR_2367;    
    In PCa, higher AR expression was found in SPOP-mutated vs non-mutated tumors (98.5% vs 97.3%, p=0.09), with improved OS outcomes after hormone targeting agents leuprolide (2125 vs 1803 days; HR: 0.71, 95% CI (0.51-0.99), p=0.04) and bicalutamide (2538 vs 1854 days; HR: 0.57, 95% CI (0.41-0.79), p<0.001). In EC, ER and PR expression was significantly lower in SPOP-mutated vs non-mutated tumors 50.8% vs 65.4% and 35.4 vs 49.5% (all q <0.05), respectively, although no difference in OS was noted in the overall EC population.These data indicate that SPOP-mutations drive different molecular and immune microenvironments in PCa and EC, with apparently opposing roles in these malignancies, and provide a rationale for tailored therapeutic approaches in SPOP-mutated PCa and EC.
  • ||||||||||  Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
    New P2 trial, HEOR:  RecoverPC: Relugolix vs GnRH Agonist in Quality of Life (clinicaltrials.gov) -  Mar 13, 2023   
    P2,  N=110, Not yet recruiting, 
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg.
    Journal:  Leuprolide Acetate and QTc Interval in Gender-Diverse Youth. (Pubmed Central) -  Mar 10, 2023   
    Only 24.2% patients had a borderline QTc (QTc 440-460?ms). No gender-diverse youth on leuprolide acetate demonstrated clinically significant QTc prolongation.